SCHEMBL7069837

SCHEMBL7069837

NCc1ccc2[nH]c(Cc3nc4cc(C(=O)NCCC(c5ccccc5)c5ccccc5)ccc4[nH]3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
EPHX2 P34913 6/20 0.46
TPSAB1 Q15661 1/20 0.46
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123647 0.92 ALDH1A1 (0.49) ALDH1A1TP53MAPTPOLBHTT
SCHEMBL7068309 0.87 NAMPT (0.50) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL7074425 0.86 ALDH1A1 (0.46) ALDH1A1TPSAB1MAPTPOLBHTT
SCHEMBL7069769 0.85 POLB (0.50) ALDH1A1EPHX2POLBHTTNAMPT
SCHEMBL7070258 0.85 PLAU (0.53) ALDH1A1CYP2C9CYP2C19MEN1KMT2A
SCHEMBL7071815 0.85 ALDH1A1 (0.44) ALDH1A1MAPTPOLBHTTNAMPT
SCHEMBL7400914 0.85 HDAC6 (0.49) ALDH1A1CYP2C9CYP2C19MAPTHPGD
SCHEMBL7075759 0.84 FLT3 (0.49) ALDH1A1POLBHTT
SCHEMBL7075818 0.84 NPC1 (0.55) ALDH1A1CYP2C19MEN1KMT2ATP53
SCHEMBL7073351 0.83 FLT3 (0.46) ALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 ALDH1A1 1860/4885EPHX2 1098/4885TPSAB1 5/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 ALDH1A1 729/4885EPHX2 1522/4885TPSAB1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.